Cargando…

European multicentre experience of staged hybrid atrial fibrillation ablation for the treatment of persistent and longstanding persistent atrial fibrillation

The management of non-paroxysmal atrial fibrillation (AF) remains controversial. We examined the efficacy and safety of the 2 stage Hybrid AF ablation approach by analysing the largest series of this technique reported so far. METHODS: The approach aims to electrically isolate the left atrial poster...

Descripción completa

Detalles Bibliográficos
Autores principales: Haywood, G.A., Varini, R., Osmancik, P., Cireddu, M., Caldwell, J., Chaudhry, M.A., Loubani, M., Della Bella, P., Lapenna, E., Budera, P., Dalrymple-Hay, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046539/
https://www.ncbi.nlm.nih.gov/pubmed/32140550
http://dx.doi.org/10.1016/j.ijcha.2019.100459
_version_ 1783501967023144960
author Haywood, G.A.
Varini, R.
Osmancik, P.
Cireddu, M.
Caldwell, J.
Chaudhry, M.A.
Loubani, M.
Della Bella, P.
Lapenna, E.
Budera, P.
Dalrymple-Hay, M.
author_facet Haywood, G.A.
Varini, R.
Osmancik, P.
Cireddu, M.
Caldwell, J.
Chaudhry, M.A.
Loubani, M.
Della Bella, P.
Lapenna, E.
Budera, P.
Dalrymple-Hay, M.
author_sort Haywood, G.A.
collection PubMed
description The management of non-paroxysmal atrial fibrillation (AF) remains controversial. We examined the efficacy and safety of the 2 stage Hybrid AF ablation approach by analysing the largest series of this technique reported so far. METHODS: The approach aims to electrically isolate the left atrial posterior wall incorporating the pulmonary veins (‘box-set’pattern). An initial video-assisted thoracoscopic (VATS) epicardial ablation is followed after a minimum of 8 weeks by endocardial radiofrequency catheter ablation. RESULTS: Of 175 patients from 4 European cardiothoracic centers, who underwent the surgical (COBRA Fusion, AtriCure Inc) 1st stage ablation, 166 went on to complete 2nd stage catheter ablation. At median follow up of 18 months post 2nd stage procedure 93/166 (56%) had remained free of AF or atrial tachycardia (AT) recurrence off antiarrhythmic drugs. 110/175 62.9% were in sinus rhythm off all antiarrhythmic drugs at last clinic follow-up (132/175 75.4% including those on antiarrhythmic drugs). 18 patients (10.8%) underwent a further re-do ablation (mean of 1.1 ablations per patient) 105/166 (63%) remained free of AF/AT recurrence off antiarrhythmic drugs following last ablation procedure. Latterly, ILRs have been implanted in patients (n = 56); 60% have remained fully arrhythmia free and 80% have shown AF burden < 5% at a median 14 months follow-up [IQR: 13.5 (8–21.5)]. Only 10.9% have reverted to persistent AF. 5 patients (2.9%) had a perioperative stroke and 4 patients (2.3%) exhibited persistent weakness of the right hemidiaphragm following stage 1 VATS epicardial ablation. One patient died following stroke (overall mortality 0.6%). CONCLUSIONS: In patients with non-paroxysmal AF with unfavourable characteristics for catheter ablation, the staged hybrid approach results in acceptable levels of freedom from recurrent atrial arrhythmia, however, complication rates are higher than with catheter ablation alone.
format Online
Article
Text
id pubmed-7046539
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-70465392020-03-05 European multicentre experience of staged hybrid atrial fibrillation ablation for the treatment of persistent and longstanding persistent atrial fibrillation Haywood, G.A. Varini, R. Osmancik, P. Cireddu, M. Caldwell, J. Chaudhry, M.A. Loubani, M. Della Bella, P. Lapenna, E. Budera, P. Dalrymple-Hay, M. Int J Cardiol Heart Vasc Original Paper The management of non-paroxysmal atrial fibrillation (AF) remains controversial. We examined the efficacy and safety of the 2 stage Hybrid AF ablation approach by analysing the largest series of this technique reported so far. METHODS: The approach aims to electrically isolate the left atrial posterior wall incorporating the pulmonary veins (‘box-set’pattern). An initial video-assisted thoracoscopic (VATS) epicardial ablation is followed after a minimum of 8 weeks by endocardial radiofrequency catheter ablation. RESULTS: Of 175 patients from 4 European cardiothoracic centers, who underwent the surgical (COBRA Fusion, AtriCure Inc) 1st stage ablation, 166 went on to complete 2nd stage catheter ablation. At median follow up of 18 months post 2nd stage procedure 93/166 (56%) had remained free of AF or atrial tachycardia (AT) recurrence off antiarrhythmic drugs. 110/175 62.9% were in sinus rhythm off all antiarrhythmic drugs at last clinic follow-up (132/175 75.4% including those on antiarrhythmic drugs). 18 patients (10.8%) underwent a further re-do ablation (mean of 1.1 ablations per patient) 105/166 (63%) remained free of AF/AT recurrence off antiarrhythmic drugs following last ablation procedure. Latterly, ILRs have been implanted in patients (n = 56); 60% have remained fully arrhythmia free and 80% have shown AF burden < 5% at a median 14 months follow-up [IQR: 13.5 (8–21.5)]. Only 10.9% have reverted to persistent AF. 5 patients (2.9%) had a perioperative stroke and 4 patients (2.3%) exhibited persistent weakness of the right hemidiaphragm following stage 1 VATS epicardial ablation. One patient died following stroke (overall mortality 0.6%). CONCLUSIONS: In patients with non-paroxysmal AF with unfavourable characteristics for catheter ablation, the staged hybrid approach results in acceptable levels of freedom from recurrent atrial arrhythmia, however, complication rates are higher than with catheter ablation alone. Elsevier 2020-01-06 /pmc/articles/PMC7046539/ /pubmed/32140550 http://dx.doi.org/10.1016/j.ijcha.2019.100459 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Paper
Haywood, G.A.
Varini, R.
Osmancik, P.
Cireddu, M.
Caldwell, J.
Chaudhry, M.A.
Loubani, M.
Della Bella, P.
Lapenna, E.
Budera, P.
Dalrymple-Hay, M.
European multicentre experience of staged hybrid atrial fibrillation ablation for the treatment of persistent and longstanding persistent atrial fibrillation
title European multicentre experience of staged hybrid atrial fibrillation ablation for the treatment of persistent and longstanding persistent atrial fibrillation
title_full European multicentre experience of staged hybrid atrial fibrillation ablation for the treatment of persistent and longstanding persistent atrial fibrillation
title_fullStr European multicentre experience of staged hybrid atrial fibrillation ablation for the treatment of persistent and longstanding persistent atrial fibrillation
title_full_unstemmed European multicentre experience of staged hybrid atrial fibrillation ablation for the treatment of persistent and longstanding persistent atrial fibrillation
title_short European multicentre experience of staged hybrid atrial fibrillation ablation for the treatment of persistent and longstanding persistent atrial fibrillation
title_sort european multicentre experience of staged hybrid atrial fibrillation ablation for the treatment of persistent and longstanding persistent atrial fibrillation
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046539/
https://www.ncbi.nlm.nih.gov/pubmed/32140550
http://dx.doi.org/10.1016/j.ijcha.2019.100459
work_keys_str_mv AT haywoodga europeanmulticentreexperienceofstagedhybridatrialfibrillationablationforthetreatmentofpersistentandlongstandingpersistentatrialfibrillation
AT varinir europeanmulticentreexperienceofstagedhybridatrialfibrillationablationforthetreatmentofpersistentandlongstandingpersistentatrialfibrillation
AT osmancikp europeanmulticentreexperienceofstagedhybridatrialfibrillationablationforthetreatmentofpersistentandlongstandingpersistentatrialfibrillation
AT cireddum europeanmulticentreexperienceofstagedhybridatrialfibrillationablationforthetreatmentofpersistentandlongstandingpersistentatrialfibrillation
AT caldwellj europeanmulticentreexperienceofstagedhybridatrialfibrillationablationforthetreatmentofpersistentandlongstandingpersistentatrialfibrillation
AT chaudhryma europeanmulticentreexperienceofstagedhybridatrialfibrillationablationforthetreatmentofpersistentandlongstandingpersistentatrialfibrillation
AT loubanim europeanmulticentreexperienceofstagedhybridatrialfibrillationablationforthetreatmentofpersistentandlongstandingpersistentatrialfibrillation
AT dellabellap europeanmulticentreexperienceofstagedhybridatrialfibrillationablationforthetreatmentofpersistentandlongstandingpersistentatrialfibrillation
AT lapennae europeanmulticentreexperienceofstagedhybridatrialfibrillationablationforthetreatmentofpersistentandlongstandingpersistentatrialfibrillation
AT buderap europeanmulticentreexperienceofstagedhybridatrialfibrillationablationforthetreatmentofpersistentandlongstandingpersistentatrialfibrillation
AT dalrymplehaym europeanmulticentreexperienceofstagedhybridatrialfibrillationablationforthetreatmentofpersistentandlongstandingpersistentatrialfibrillation